Literature DB >> 23631423

Incidence and management of elevated intraocular pressure with antivascular endothelial growth factor agents.

Gelareh Abedi1, Ron A Adelman, Sarwat Salim.   

Abstract

PURPOSE: To review recent literature regarding ocular hypertension following intravitreal antivascular endothelial growth factors (anti-VEGF).
METHOD: An electronic literature search was performed using MEDLINE, OVID, and PubMed. Key search terms were elevated IOP, anti-VEGF, sustained IOP elevation in anti-VEGF, chronic intraocular pressure elevation in anti-VEGF, high IOP with anti-VEGF, acute elevation in intraocular pressure with anti-VEGF, glaucoma and anti-VEGF. RESULT: Transient elevation of intraocular pressure after intravitreal anti-VEGF injection is due to temporary increase in volume, and the acute spike generally does not affect a healthy eye. Caution should be taken in a glaucomatous eye, and pretreatment with an IOP-lowering medication is recommended. Persistent elevation of intraocular pressure is more common than previously thought and may be correlated to several factors including increased number of intravitreal injections.
CONCLUSION: Persistent ocular hypertension may be associated with intravitreal anti-VEGF injections. Physicians should be aware of this condition and monitor their patients for persistent ocular hypertension, especially in eyes with preexisting glaucoma. Prompt diagnosis and treatment can prevent potential loss of vision.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23631423     DOI: 10.3109/08820538.2013.771195

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  8 in total

1.  The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.

Authors:  Esra Omay; Ufuk Elgin; Emine Sen; Pelin Yilmazbas
Journal:  Int Ophthalmol       Date:  2016-01-16       Impact factor: 2.031

2.  Reduction of Intraocular Pressure Spikes Due to Intravitreal Bevacizumab Injections by Scleral Indentation with Cotton Swab or Digital Ocular Massage: Innovative Techniques Compared.

Authors:  Raffaele Nuzzi; Simona Scalabrin; Alice Becco
Journal:  Clin Ophthalmol       Date:  2020-08-27

3.  Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.

Authors:  Marcel N Menke; Carsten Framme; Mathias Nelle; Markus R Berger; Veit Sturm; Sebastian Wolf
Journal:  BMC Ophthalmol       Date:  2015-03-08       Impact factor: 2.209

4.  Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure.

Authors:  Ashiyana Nariani; Blake Williams; Seenu M Hariprasad
Journal:  Indian J Ophthalmol       Date:  2016-09       Impact factor: 1.848

Review 5.  Use of Anti-VEGF Agents in Glaucoma Surgery.

Authors:  Mark Slabaugh; Sarwat Salim
Journal:  J Ophthalmol       Date:  2017-06-27       Impact factor: 1.909

6.  Focal vitreomacular traction: Resolution after ocular massage.

Authors:  José Javier García-Medina; Mónica Del-Río-Vellosillo; Elena Rubio-Velázquez; María Dolores López-Bernal; Juan José Zafra-Pérez
Journal:  Am J Ophthalmol Case Rep       Date:  2019-02-22

Review 7.  Issues with Intravitreal Administration of Anti-VEGF Drugs.

Authors:  Marc Schargus; Andreas Frings
Journal:  Clin Ophthalmol       Date:  2020-03-23

8.  Acute and subacute macular and peripapillary angiographic changes in choroidal and retinal blood flow post-intravitreal injections.

Authors:  Nadhini Arumuganathan; Maximilian Robert Justus Wiest; Mario Damiano Toro; Timothy Hamann; Katrin Fasler; Sandrine Anne Zweifel
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.